Insiders Could Have Profited By Holding onto Ocumension Therapeutics Shares Despite 12% Drop

Despite the fact that Ocumension Therapeutics' (HKG:1477) value has dropped 12% in the last week insiders who sold CN¥79m worth of stock in the past 12 months have had less success. Given that the average selling price of CN¥4.94 is still lower than the current share price, insiders would probably have been better off keeping their shares.

Although we don't think shareholders should simply follow insider transactions, we do think it is perfectly logical to keep tabs on what insiders are doing.

Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit.

The Last 12 Months Of Insider Transactions At Ocumension Therapeutics

In the last twelve months, the biggest single sale by an insider was when the Non-Executive Chairman of the Board, Lian Yong Chen, sold HK$79m worth of shares at a price of HK$4.94 per share. We generally don't like to see insider selling, but the lower the sale price, the more it concerns us. The silver lining is that this sell-down took place above the latest price (HK$4.35). So it may not shed much light on insider confidence at current levels. Lian Yong Chen was the only individual insider to sell shares in the last twelve months.

You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

Check out our latest analysis for Ocumension Therapeutics

For those who like to find hidden gems this free list of small cap companies with recent insider purchasing, could be just the ticket.

Does Ocumension Therapeutics Boast High Insider Ownership?

Looking at the total insider shareholdings in a company can help to inform your view of whether they are well aligned with common shareholders. Usually, the higher the insider ownership, the more likely it is that insiders will be incentivised to build the company for the long term. Ocumension Therapeutics insiders own about HK$515m worth of shares. That equates to 15% of the company. We've certainly seen higher levels of insider ownership elsewhere, but these holdings are enough to suggest alignment between insiders and the other shareholders.

What Might The Insider Transactions At Ocumension Therapeutics Tell Us?

There haven't been any insider transactions in the last three months -- that doesn't mean much. It's heartening that insiders own plenty of stock, but we'd like to see more insider buying, since the last year of Ocumension Therapeutics insider transactions don't fill us with confidence. Therefore, you should definitely take a look at this FREE report showing analyst forecasts for Ocumension Therapeutics.

If you would prefer to check out another company -- one with potentially superior financials -- then do not miss this free list of interesting companies, that have HIGH return on equity and low debt.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.